Selected Grants
Phase I study of PD-0332991 for pediatric patiens with retinoblastoma protein (RB)-positive recurrent or refractory central nervous system (CNS) tumors.
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2014 - 2026Genome Editing for the Treatment of Neurofibromatosis Type I
ResearchCollaborator · Awarded by Gilbert Family Foundation · 2022 - 2024Exploring the Use of Gene Therapies to Treat Neurofibromatosis Type I
FellowshipMentor · Awarded by National Institutes of Health · 2022 - 2024A phase 2b trial of the MEK 1/2 inhibitor (MEKi) PD-0325901 in adult and pediatric patient with neurofibromatosis type 1 (NF1)-associated inoperable plexiform neurofibromas (PNs) that are causing significant morbidity
Clinical TrialPrincipal Investigator · Awarded by SpringWorks Therapeutics · 2020 - 2023Targeting epigenetic dysregulation in pediatric cancer
ResearchCo Investigator · Awarded by Dana-Farber Cancer Institute · 2019 - 2022Phase I study of PD-0332991 for pediatric patiens with retinoblastoma protein (RB)-positive recurrent or refractory central nervous system (CNS) tumors.
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2014 - 2026Genome Editing for the Treatment of Neurofibromatosis Type I
ResearchCollaborator · Awarded by Gilbert Family Foundation · 2022 - 2024Exploring the Use of Gene Therapies to Treat Neurofibromatosis Type I
FellowshipMentor · Awarded by National Institutes of Health · 2022 - 2024A phase 2b trial of the MEK 1/2 inhibitor (MEKi) PD-0325901 in adult and pediatric patient with neurofibromatosis type 1 (NF1)-associated inoperable plexiform neurofibromas (PNs) that are causing significant morbidity
Clinical TrialPrincipal Investigator · Awarded by SpringWorks Therapeutics · 2020 - 2023Targeting epigenetic dysregulation in pediatric cancer
ResearchCo Investigator · Awarded by Dana-Farber Cancer Institute · 2019 - 2022MAIN STUDY: Developing Evidence-Based Crieteria for Initiating Treatment fo NF1-OPG.
Clinical TrialPrincipal Investigator · Awarded by Children's Tumor Foundation · 2015 - 2021Visual Field Outcomes in Pediatric Patients with NF1-associated Optic Pathway Gliomas
ResearchPrincipal Investigator · Awarded by Boston Children's Hospital · 2018 - 2019Expansion of the AYA Oncology Initiative at Duke University
ResearchPrincipal Investigator · Awarded by St. Baldrick's Foundation · 2016 - 2018Dissecting the role of injury is sarcoma formation
ResearchPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2015 - 2017Dissecting the role of injury is sarcoma formation
ResearchPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2015 - 2017External Relationships
- AstraZeneca
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.